engleski

GLP-1 receptor – Do we really know what we’re looking at?

We read with great interest a recent comprehensive review covering the knowns and the unknowns of glucagon-like peptide-1 (GLP-1) by McLean et al. (McLean et al., 2020). GLP-1 is best known for its incretin effects first described in the 1980s that provided strong foundations for the development of GLP-1 targeting drugs and revolutionized pharmacotherapy of insulin resistance in the 2000s (Drucker et al., 2017). Nevertheless, as evident from (McLean et al., 2020), we can expect that the glory days of GLP-1 are far from over and that this incretin is going to be even more important for the doctors of tomorrow based on many of its relevant actions, especially in the cardiovascular and central nervous system. A review by McLean et al. (McLean et al., 2020) drew our attention not only because it covers a timely and captivating topic, but because it clearly emphasizes serious limitations and methodological caveats regarding GLP-1 receptor (GLP-1R) expression analysis. Failure to acknowledge methodological caveats either willfully or through ignorance far too often leads to misinterpretation of the results and formation of unjustified conclusions challenging to rectify once they pass under the peer-review radar, and unfortunately – they often do. In this letter, we wish to acknowledge the intention of McLean et al. (McLean et al., 2020) to warn the readers about the methodological drawbacks, especially those regarding the specificity and sensitivity of GLP- 1R antisera and supplement the „Caveats and limitations“ section (McLean et al., 2020) with our own experience and comment regarding bs-1559R anti- GLP-1R rabbit polyclonal antibody.

GLP-1 ; antibodies ; research methodology

nije evidentirano